Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET (ARTE-MISO)

Ankara University

Status: Completed

Conditions: Radioembolization; Radiotherapy; Cancer; Positron Emission Tomography

Treatments: Diagnostic Test: 18F-Fluoromisonidazole PET

Study type: Observational

Funder types: Other

Identifiers

NCT06027021

ARTE-MISO

Details and patient eligibility

About

Hypoxia is a known factor for resistance to radiotherapy in tumors. Response to transarterial radioembolization is known to be variable between different patients even if the same dose of radiation was delivered. In this study the investigators aim to quantify the hypoxia in the primary and secondary tumors of liver with 18F-FMISO PET before radioembolization and to prove any effect of the hypoxia, if present, on the dose that should be delivered to tumor to ensure treatment response.

Enrollment: 64 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with colorectal carcinoma with liver metastasis or hepatocellular carcinoma.
• Is not eligible for surgery
• Above 18 years old
• The patients who are referred for transarterial radioembolization treatment to Ankara University School of Medicine Department of Nuclear Medicine.

Exclusion criteria

• Patients with ECOG performance score >1
• Claustrophobia
• Life expectancy shorter than 3 months
• Pregnant or breast-feeding patients

Trial design

64 participants in 1 patient group

Treatment group

Description:

Patients received radioembolization with hepatocellular cancer or colorectal cancer liver metastases

Treatment:

Diagnostic Test: 18F-Fluoromisonidazole PET